Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
7 luglio 2026
Herbert Smith Freehills Kramer advises MCB on acquisition bridge facility for Genel Energy plc
Herbert Smith Freehills Kramer has advised The Mauritius Commercial Bank Limited (MCB) on its provision of a committed US$125,000,000 acquisition bridge …
7 luglio 2026
Herbert Smith Freehills Kramer advises EQT on acquisition of Orikan
HSF Kramer has advised EQT Group on the acquisition of Orikan, a provider of integrated parking, enforcement, and compliance technology solutions, from …
6 luglio 2026
Herbert Smith Freehills Kramer advises the shareholder of Kuhmichel group on the sale to SurfacePrep
Herbert Smith Freehills Kramer has advised the shareholders of the Kuhmichel group on the sale to SurfacePrep group.